SYM 250110 35.00P (SYM250110P35000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

SYM250110P35000

Watchlist

0.00
0.000.00%

15min DelayClose Jan 7 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Symbotic Raised to Buy From Neutral by DA Davidson
Dow Jones07:12 ET · Ratings
D.A. Davidson Maintains Symbotic(SYM.US) With Buy Rating, Cuts Target Price to $35
Moomoo News06:35 ET · Ratings
ChatGPT Moment For Robotics Is Around The Corner Says Nvidia CEO
Benzinga12:42 ET
Insider Sale: Director at $SYM (SYM) Sells 2,000 Shares
Quiver QuantitativeJan 6 20:16 ET
Symbotic Appoints New Chief Technology Officer
MT NewswiresJan 6 16:27 ET
Symbotic: Kuffner Succeeds George Dramalis >SYM
Dow JonesJan 6 16:00 ET

Comments

Moomoo News Global

Jan 6 02:12

Columns Is the Robotics Industry Poised for a Surge in 2025? Here Are the Investment Opportunities

Scheduled to officially start on January 7, 2025, the Consumer Electronics Show (CES)—a premier tech event that showcases both current products and futuristic concepts from large and small tech firms—once again captured global attention.
At CES 2025, $NVIDIA (NVDA.US)$ is undoubtedly one of the brightest stars on stage. Jensen Huang will personally showcase the company's latest breakthroughs in AI, robotics...

The CES showcase is here! Where's the next breakthrough in AI?

104

186

Phil Dunn

Dec 21, 2024 11:00

Review of the very harsh 3rd week Dec

Devastating Crash of $Novo-Nordisk A/S (NVO.US)$ and Strong Rebound of $NVIDIA (NVDA.US)$ on Black Friday.
I made a difficult but crucial decision on Friday to sell off losing positions at pre-market which were moving downtrend so badly like $Novo-Nordisk A/S (NVO.US)$ , $D.R. Horton (DHI.US)$ , $Huntington Ingalls Industries (HII.US)$ , $MarketAxess (MKTX.US)$ . Especially obesity drug giant NVO which collapsed 25% at pre-market after disappointing trial results o...